Significant fracture risk reductions following 18 months of treatment1

TYMLOS significantly reduced the risk of vertebral fractures1

Percentage of postmenopausal women with osteoporosis with new vertebral fractures at 18 months1

Proportion of postmenopausal women with vertebral fractures after 18 months treatment with TYMLOS vs placebo

P<0.0001.1
Results reported in the modified intent-to-treat (ITT) population, which included patients who had both pretreatment and posttreatment spine radiographs.1
Primary endpoint.1

7x fewer women on TYMLOS experienced new vertebral fractures at 18 months versus those on placebo1

TYMLOS significantly reduced the risk of nonvertebral fractures1

Cumulative incidence of nonvertebral fractures* at 19 months (18 months of treatment plus 1 month of follow-up without treatment)1

Nonvertebral fracture risk after 18 months TYMLOS treatment

Nonvertebral fractures excluded those of the sternum, patella, toes, fingers, skull, and face, and those associated with high trauma.1

P=0.049.1

P-value based on the log-rank test.1

Results reported in ITT population, which included patients randomized in the efficacy study.1

Secondary endpoint.2

Nonvertebral fractures excluded those of the sternum, patella, toes, fingers, skull, and face, and those associated with high trauma.1

P-value based on the log-rank test.1

P=0.049.1

Results reported in ITT population, which included patients randomized in the efficacy study.1

Secondary endpoint.2

Risk reductions across demographics1

TYMLOS demonstrated consistent reductions in the risk of vertebral and nonvertebral fractures regardless of1:

Age

BMD at baseline

Years since menopause

Presence or absence
of prior vertebral or
nonvertebral fracture

View BMD results from the
TYMLOS efficacy study

References: 1. TYMLOS™ [prescribing information]. Waltham, MA: Radius Health, Inc; 2017. 2. A randomized, double-blind, placebo-controlled, comparative phase 3 multicenter study to evaluate the safety and efficacy of BA058 for injection for prevention of fracture in ambulatory postmenopausal women with severe osteoporosis and at risk of fracture [supplement 2]. Waltham, MA: Radius Health, Inc; 2015. http://jamanetwork.com/data/Journals/JAMA/935644/JOI160092supp2_prod.pdf. Accessed June 14, 2017.

This site is intended for HCPs in the United States.

All other trademarks are the property of their respective owners.

© 2017 Radius Health, Inc.   All rights reserved.    12/17.   TYM-US-00847

This site is intended for HCPs in the United States.
TYMLOS is a trademark of Radius Health, Inc.
All other trademarks are the property of their respective owners.

© 2017 Radius Health, Inc.
All rights reserved. 12/17.
TYM-US-00847

Back to Top